M
Mehrdad Abedi
Researcher at University of California, Davis
Publications - 104
Citations - 3531
Mehrdad Abedi is an academic researcher from University of California, Davis. The author has contributed to research in topics: Stem cell & Transplantation. The author has an hindex of 25, co-authored 83 publications receiving 2819 citations. Previous affiliations of Mehrdad Abedi include University of Massachusetts Medical School & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Advances in graft-versus-host disease biology and therapy
TL;DR: This Review highlights the recent advances in understanding the pathophysiology of GVHD and its treatment, with a focus on manipulations of the immune system that are amenable to clinical application.
Journal ArticleDOI
Participation of bone marrow derived cells in cutaneous wound healing
Evangelos V. Badiavas,Evangelos V. Badiavas,Evangelos V. Badiavas,Mehrdad Abedi,Janet Butmarc,Vincent Falanga,Peter J. Quesenberry +6 more
TL;DR: It is shown that bone marrow might be a valuable source of stem cells for the skin and possibly other organs and that Wounding could be a stimulus for bone marrow derived stem cells to travel to organs and aid in the regeneration of damaged tissue.
Journal ArticleDOI
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah,Armin Ghobadi,Olalekan O. Oluwole,Aaron C Logan,Nicolas Boissel,Ryan D. Cassaday,Thibaut Leguay,Michael R. Bishop,Max S. Topp,Dimitrios Tzachanis,Kristen M. O'Dwyer,Martha Arellano,Yi Lin,Maria R. Baer,Gary J. Schiller,Jae H. Park,Marion Subklewe,Mehrdad Abedi,Monique C. Minnema,William G. Wierda,Daniel J. DeAngelo,Patrick J. Stiff,Deepa Jeyakumar,Chaoling Feng,Jinghui Dong,Tong Shen,Francesca Milletti,John M. Rossi,Remus Vezan,Behzad Kharabi Masouleh,Roch Houot +30 more
TL;DR: The pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.
Journal ArticleDOI
Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response
Richard P. Junghans,Richard P. Junghans,Qiangzhong Ma,Qiangzhong Ma,Ritesh Rathore,Erica M. Gomes,Anthony Bais,Agnes Lo,Agnes Lo,Mehrdad Abedi,Robin Davies,Howard Cabral,A. Samer Al-Homsi,Stephen I. Cohen +13 more
TL;DR: Chimeric antigen receptor (CAR)‐modified “designer” T cells (dTc) against PSMA selectively target antigen‐expressing cells in vitro and eliminate tumors in vivo.
Journal ArticleDOI
Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Ischemic and Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial Findings
Susanna Soon Chun Park,Gerhard Bauer,Mehrdad Abedi,Suzanne Pontow,Athanasios Panorgias,Ravi S. Jonnal,Robert J. Zawadzki,John S. Werner,Jan A. Nolta +8 more
TL;DR: Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration.